Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype

NCT06486883 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

200

Enrollment

OTHER

Sponsor class

Conditions

Advanced Breast Cancer
Advanced Breast Carcinoma
Hormone Receptor Positive Breast Carcinoma

Interventions

DRUG: Trastuzumab deruxtecan (T-DXd, DS-8201a)
DRUG: CDK4/6i plus ET

Sponsor

MedSIR